-PML/RARA loss or detachment from target promoters suffices to differentiate APL cells.
Introduction
Acute promyelocytic leukemia (APL) is characterized by gene fusions involving Retinoic Acid Receptor-alpha (RARA) gene. The most common t (15;17) translocation fuses PML to RARA, yielding the PML/RARA fusion oncoprotein. PML, the key organizer of Nuclear Bodies (NB), is involved in redox sensing and hence confers sensitivity to arsenic trioxide. [1] [2] [3] PML/RARA is a potent transcriptional repressor of retinoic acid (RA) signaling that interferes with gene expression programs involved in both hematopoietic progenitor self-renewal and terminal myeloid cell differentiation. 4, 5 Treatment of APL patients with RA induces terminal differentiation and transient remissions. Mechanistically, this is believed to reflect transcriptional reactivation of PML/RARA-silenced genes by RA, the ligand for RARA and PML/RARA, 6 while RA-triggered PML/RARA degradation accounts for loss of self-renewal. 7, 8 Arsenic definitively cures a substantial proportion of patients as a single agent. [9] [10] [11] Ex vivo studies demonstrated that arsenic primarily induces apoptosis of APL cells, 12 although subsequent studies demonstrated partial or complete differentiation ex vivo and in vivo, respectively. 13 Molecularly, arsenic degrades PML/RARA, but otherwise does not directly affect transcriptional regulation by RARA, raising the issue of the basis for differentiation. 14, 15 Arsenic also acts on normal PML to promote loss of self-renewal, likely explaining its clinical potency. 7, 16 In normal cells, RARA is always associated to RXRs (Retinoid X Receptor) the universal partners of type II nuclear receptors to bind their responsive elements (RARE). RA binds to RARs inducing conformational changes within the RXRs/RARs complexes, thus resulting in enhancement of DNA binding, release of co-repressors, recruitment of co-activator complexes, and transcriptional activation of target genes.
The RA pathway plays an important role in determining and regulating differentiation [27] [28] [29] The presence of RXRA in the PML/RARA complex greatly enhances its ability to bind DNA and to recognize highly degenerate sites. 21, 22 Additionally, RXRA may provide an independent repression signal through its sumoylation, the latter being sharply enhanced by PML/RARA.
25,30
Accordingly, a PML/RARA mutant defective for RXR binding fails to initiate APL in vivo, 25 while silencing of RXRA induces apoptosis ex vivo.
31
Here, we show that RXR excision from PML/RARA-driven APL relaxes association of the fusion and its target genes, inducing terminal differentiation of leukemic cells. Inactivation of PML/RARA by RNA interference also triggers differentiation. These unexpected observations provide a mechanistic basis for arsenic-induced APL differentiation.
Materials and methods

Cell culture and Retroviral transductions
cDNAs encoding PML/RARA and RARA were previously described. 25 The
Cre-ERT2 cDNA was inserted in MSCV-IRES-cRed (kind gift of R. Williams). The
For personal use only. on January 29, 2018. by guest www.bloodjournal.org From 5 murine RXRA WT and RXRA K113R cDNAs (kind gift of C. Egly) were inserted in MSCV-Babe-IRES-cRed. MSCV-FLT3ITD-IRES-GFP construct was previously described. 32 ShRNA constructs were purchased from Sigma-Aldrich. The two shRNA constructs targeting human PML (5'-CACCCGCAAGACCAACAACAT-3', 5'-GTGTACCGGCAGATTGTGGAT-3'), were inserted into pLKO.1-CMV-tGFP.
Bone marrow cells from 5-fluorouracil-treated mice (C57BL/6JRj) depleted in mature myeloid and lymphoid cells were cultured overnight with interleukin-3 (IL-3), IL-6 (10 ng/ml), and stem cell factor (100 ng/ml) (Eurobio Abcys Cell cycle profiles were assessed using propidium iodide. were obtained using RMA normalization. Threshold: 2 for human, 1.8 for mice, unless otherwise indicated. Expression profiles were normalized in batch using RMA method, independently in each series, yielding normalized log2 intensity measures.
Protein and cells analyses
Log2 ratios were then obtained from these log2 intensities, using control samples as reference. Given two conditions A and B, in order to assess whether or not the genes up-regulated (respectively down-regulated) in these two conditions are significantly overlapping or not, we ranked the genes for both conditions and performed a chi2 test measuring the overlap between the top N genes in condition A and the top N genes in condition B (N ranging from 100 to 1200). 
Results
RXRA
RXRA loss induces differentiation and apoptosis.
We next investigated the consequences of acute RXR ablation on survival and differentiation. We thus crossed PML/RARA transgenic mice driven by the MRP8 Transduced marrows were transplanted in irradiated Nude mice yielding aggressive APLs after 16 weeks which closely resemble previously studied ones (data not shown). These APLs were then transduced with a retrovirus co-expressing Cre-ERT2
and Cherry, yielding a transplantable APL where Tamoxifen (4-OHT) induces ablation of both RXRA and RXRB (Figure 2A 
(
Figure 5B-C), demonstrating that in vivo, down-regulation of PML/RARA expression promotes terminal myeloid differentiation.
Reassessing the basis for arsenic-induced differentiation
Similar to RXRA ablation or PML/RARA silencing, arsenic triggers differentiation and apoptosis whose respective extents, however, greatly vary with the experimental system used. 12, 13, 15 To investigate the role of arsenic-initiated PML/RARA loss in transcriptional regulation, we first compared the mRNAs expression profiles of the NB4 APL cells treated with RA or arsenic. Up and downregulated genes in response to these two unrelated agents were found to be extremely redundant (chi2 test p value < 1e-50), whatever the time considered ( Figure 5D upper panel and 5E). Critically, a similar situation was observed in APL mice ( Figure 5D lower panel, 5E, Figure S2 ). 7 Thus, RA and arsenic regulate a common set of genes, most likely by a promoter clearance mechanism.
Discussion
Our results demonstrate that RXRA and its sumoylation play a key role in Figure 6 ). Yet, growth factors enhance survival and promote terminal differentiation by arsenic ex vivo 57, 58 . Our results could thus For For For personal use only. on January 29, 2018. by guest www.bloodjournal.org From
